Insider Trading February 20, 2026

Tempus AI Chief Executive Disposes $10.5M in Stock While Receiving Large RSU Award

Eric Lefkofsky carried out structured sales under a 10b5-1 plan on Feb. 19 and received fully vested RSUs one day later

By Avery Klein TEM
Tempus AI Chief Executive Disposes $10.5M in Stock While Receiving Large RSU Award
TEM

Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky sold roughly $10.5 million of Class A common stock on February 19, 2026, under a pre-established 10b5-1 plan, and on February 20 received 263,430 fully vested restricted stock units. The transactions included multiple tranches sold at prices between $58.31 and $59.70 and a separate sale to cover tax obligations on vested RSUs. Following the activity, Lefkofsky retains direct and substantial indirect holdings through multiple entities.

Key Points

  • Tempus AI CEO Eric P. Lefkofsky sold approximately $10.5 million of Class A common stock on February 19, 2026, under a 10b5-1 trading plan, and separately sold shares to cover tax obligations on vested RSUs.
  • On February 20, 2026, Lefkofsky received 263,430 fully vested restricted stock units tied to his 2025 bonus award and certified performance-based stock units.
  • Following the transactions, Lefkofsky maintains substantial direct and indirect holdings through multiple entities; the disclosure also notes recent product advances in AI-driven diagnostics and new analyst coverage with Outperform ratings.

Eric P. Lefkofsky, CEO and Chairman of Tempus AI, Inc. (EXCHANGE:TEM), executed a series of stock dispositions on February 19, 2026, disposing of Class A common shares valued at approximately $10.5 million. The sales were carried out under a 10b5-1 trading plan and occurred across several tranches, with transaction prices ranging from $58.31 to $59.70 per share. In an adjacent transaction, Lefkofsky sold additional shares specifically to satisfy tax obligations arising from vesting restricted stock units.

Details of the February 19 sales

The February 19 activity involved multiple blocks of shares recorded at different weighted average prices and attributed to indirect ownership through entities described in the filing. Tranches included:

  • 8,552 shares sold at a weighted average price of $58.31;
  • 23,775 shares sold at a weighted average price of $59.04;
  • 923 shares sold at an average price of $59.70. These shares were indirectly owned by Gray Media, LLC.
  • 33,717 shares sold at a weighted average price of $58.31;
  • 95,567 shares sold at a weighted average price of $59.04;
  • 3,716 shares sold at an average price of $59.70. These shares were indirectly owned by Blue Media, LLC.
  • Separately, 13,587 shares were sold at a weighted average price of $59.05, with individual prices ranging from $58.71 to $59.38; proceeds from this block, totaling $802,312, were designated to cover tax obligations tied to vested restricted stock units.

Aggregating the listed tranches yields total sale proceeds of $9,787,605 from the primary 10b5-1 transactions, plus the $802,312 sale to satisfy tax obligations, bringing the combined amount to roughly $10.5 million.

Subsequent vesting and award certification

On February 20, 2026, Lefkofsky was credited with 263,430 shares of Class A common stock at a $0 purchase price. Those shares represent fully vested restricted stock units tied to his 2025 bonus award and shares certified as earned under a performance-based stock unit grant dated August 7, 2025.

Post-transaction ownership

After these transactions, the filing indicates Lefkofsky directly owns 2,253,056 shares of Class A common stock. He also holds indirect ownership stakes through multiple entities, with the filing listing the following balances:

  • Gray Media, LLC: 8,908,283 shares;
  • Blue Media, LLC: 15,922,469 shares;
  • 346 Long LLC: 406 shares;
  • Lefkofsky Family 2025 GRAT: 10,000,000 shares;
  • Black Media, LLC: 206 shares;
  • Lefkofsky Family Foundation: 832,131 shares;
  • Vas.org Foundation: 250,000 shares.

Market context provided in the filing

At the time of the disclosures, the company’s stock was trading at $58.37 per share, a level that the filing notes is 44% below its 52-week high of $104.32. The filing also records that shares had risen 12% over the preceding week. An analysis cited in the disclosure described the stock as appearing overvalued relative to its Fair Value estimate, placing it among companies listed as most overvalued under that evaluation.

Recent company product and research updates

Separately, the company reported advancements in its AI-driven diagnostic efforts. Tempus AI announced the launch of an HRD-RNA algorithm designed to identify Homologous Recombination Deficiency, intended to help flag patients who may be candidates for platinum-based chemotherapy or PARP inhibitor therapy. The company also disclosed results from a study indicating its Immune Profile Score test improves prediction of patient outcomes for immunotherapy by combining multiple clinical and immune-related biomarkers, exceeding traditional single-marker approaches in predicting responses to immune checkpoint inhibitors.

Analyst coverage noted in the filing

The filing references initiation of analyst coverage by two broker-dealers. Mizuho began coverage with an Outperform rating and set a price target of $100.00. Baird also initiated coverage with an Outperform rating and assigned a $59.00 price target. Both firms are cited as recognizing the company’s role in precision oncology diagnostics and AI-enabled healthcare data services.

Takeaway

The documented activity shows a near-term disposition of equity by the CEO under a trading plan alongside a sizable issuance of vested equity compensation. The filing provides a detailed accounting of the tranches sold, subsequent vested awards, and the aggregate direct and indirect holdings retained by the Reporting Person after the transactions.

Risks

  • The filing notes the company’s share price was 44% below its 52-week high, indicating price volatility that could affect investor sentiment - relevant to equity and healthcare sectors.
  • An analysis included in the disclosure describes the stock as appearing overvalued relative to its Fair Value estimate, which may influence valuation risk for investors in the healthcare and diagnostics space.
  • The CEO’s sales, even when executed under a 10b5-1 plan, could be interpreted by some market participants as a change in insider liquidity preference, introducing short-term uncertainty for the stock.

More from Insider Trading

Clean Harbors Director Executes $204,802 Sale as Company Reports Strong Q4 and Pushes M&A Agenda Feb 21, 2026 Clean Harbors Executive Disposes Nearly $1.0M in Stock as Company Posts Strong Q4 Feb 21, 2026 Clean Harbors CFO Disposes $784K in Shares as Company Reports Strong Quarter and Pursues Acquisition Feb 21, 2026 Travelers Executive Vice President Records $1.74 Million Share Sale as Company Posts Strong Quarter Feb 21, 2026 Genasys Director Buys $50,404 of Stock; Company Reports Mixed Q1 Results Feb 21, 2026